DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kelley RK, Abou-Alfa GK, Bendell JC. , et al.
Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses.
J Clin Oncol 2017;
35: 4073-4073
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.